Liraglutide Treatment to Patients With Severe Renal Insufficiency

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Incretin-based therapy for the treatment of patients with type 2 diabetes mellitus (T2D) is new and fundamentally different from the classical treatments with oral antidiabetic agents and insulin. The novel and original aspect of this investigator-initiated study is the focus on treatment with an incretin-based agent (the GLP-1 analogue liraglutide) in T2D patients with severely reduced kidney function. At present there is virtually no knowledge of the physiology and clinical implications of the role of incretin hormones and incretin-based therapy in this group of diabetic patients.The aim of the study is to establish an evidence-based rationale for introducing a GLP-1 analogue to the limited armamentarium of antidiabetic drugs for patients with type T2D and severe renal insufficiency. The overall hypothesis is that patients with T2D and severe renal insufficiency will tolerate and benefit from treatment with the GLP-1 analogue liraglutide, hereby improving glycaemic control and reducing risk factors of cardiovascular disease

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure

NCT02284230

Kidney Failure, Chronic Prediabetic State

WITHDRAWN PHASE2

Liraglutide as add-on to Insulin in Type 1 Diabetes

NCT02092896

Diabetes Diabetes Mellitus, Type 1

COMPLETED PHASE3

Elimination of Incretin Hormones in Patients With Severe Kidney Failure

NCT01391884

Uremia

COMPLETED

Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes

NCT01499108

Type 2 Diabetes

COMPLETED PHASE4

Liraglutide in Type 1 Diabetes

NCT01612468

Diabetes Mellitus, Type 1 Overweight

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus End-stage Renal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

T2D, Dialysis, Liraglutide

Daily liraglutide treatment Chronic dialysis treatment

Group Type ACTIVE_COMPARATOR